Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue 5, 1997, Pages 973-980

  Robinson, M ^a   Maton, P N ^a   Rodriguez, S ^a   Greenwood, B ^a   Humphries, T J ^b  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LY 307640; PROTON PUMP INHIBITOR; RABEPRAZOLE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENDOSCOPY; ESOPHAGUS PH; FEMALE; GASTRIN BLOOD LEVEL; GASTROESOPHAGEAL REFLUX; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICS; STOMACH PH;

EID: 0030845923     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1997.00244.x     Document Type: Article

References (26)

1. Orlando RC. Reflux esophagitis. In: Yamada T. Alpers DH, eds. Textbook of Gastroenterology. Philadelphia: Lippincott, 1991: 1123-47.
2. Olbe L, Lundell L. Medical treatment of reflux esophagitis. Hepatogastroenterol 1992; 39: 322-4.
3. Sanders SW. Pathogenesis and treatment of acid peptic disorders: comparison of proton pump inhibitors with other antiulcer agents. Clin Ther 1996; 18: 2-34.
4. Orr WC, Robinson MG, Humphries TJ, Antonello J, Cagliola A. Dose-response effect of famotidine on patterns of gastro-oesophageal reflux. Aliment Pharmacol Ther 1988; 2: 229-35.
5. Robinson M, Maton PN, Allen ML, et al. Effect of different doses of omeprazole on 24-hour oesophageal acid exposure in patients with gastro-oesophageal reflux. Aliment Pharmacol Ther 1991; 5: 645-51.
6. Robinson M, Decktor DL, Stone RC, et al. and the Famotidine/ GERD, Investigation Group. Famotidine (20 mg) b.d. relieves gastro-oesophageal reflux symptoms in patients without erosive oesophagitis. Aliment Pharmacol Ther 1991; 5: 631-43.
7. Simon TJ, Berenson MM, Berlin RG, et al. Randomized, placebocontrolled comparison of famotidine 20 mg b. d. or 40 mg b.d. in patients with erosive oesophagitis. Aliment Pharmacol Ther 1994; 8: 71-9.
8. Chiba N, de Gara CJ, Burget DW, Wilkinson J, Hunt RH, Rapidity of healing in GERD. a comparison of different drug classes by meta-analysis. Gastroenterol 1993; 140: 53 (Abstract).
9. Castell DO, Johnston BT. Gastroesophageal reflux disease. Current strategies for patient management. Arch Fam Med 1996; 5: 221-7.
10. Sontag SJ, Hirschowitz BI, Holt S, et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter Study. Gastroenterol 1992; 102: 109-18.
11. Huber R, Kohl B, Sachs G, Senn-Bilfinger J, Simon WA, Sturm E. Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 1995; 9: 363-78.
12. +-ATPase. Biochem Pharmacol 1995; 49: 1729-34.
13. Fujisaki H, Shibata H, Oketani K, et al. Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione. Biochem Pharmacol 1991; 42: 321-8.
14. Humphries TJ, Cloud ML, Enas N, Bassion S, McNamara M. and the US Rabeprazole Gastric Ulcer Study Group. Rabeprazole (E3810, LY307640) achieves high rates of healing in active gastric ulcer. Gastroenterol 1996; 110: 138(Abstract).
15. Cloud ML, Olovich K, Enas N, Bassion S, Humphries T. LY307640 versus placebo in healing duodenal ulcers. Gastroenterol 1995; 108: 73(Abstract).
16. Cloud ML, Olovich K, Enas N, Bassion S, Humphries T. LY307640 versus placebo in healing erosive, ulcerative reflux esophagitis. Gastroenterol 1995; 108: 73(Abstract).
17. Wienbeck M, Barnert J. Epidemiology of reflux disease and reflux esophagitis. Scand J Gastroenterol 1989; 24(Suppl. 156): 7-13.
18. Robinson M, Earnest D, Maton PN, et al. Frequent heartburn symptoms should not be ignored in subjects who self-treat with antacids. Gastroenterol 1996; 110: 241 (Abstract).
19. Sandmark S, Carlsson R, Fausa O, Lundell L. Omeprazole or ranitidine in the treatment of reflux esophagitis: results of a double-blind, randomized. Scandinavian multicenter study. Scand J Gastroenterol 1988; 23: 625-32.
20. Bate CM, Keeling PWN, O'Morain CA, et al. Omeprazole heals reflux oesophagitis in a greater proportion of patients than cimetidine, assessed endoscopically, histologically, and symptomatically. Hepatogastroenterol 1989; 36: 279.
21. Robinson M, Decktor DL, Maton PN, et al. Omeprazole is superior to ranitidine plus metoclopramide in the short-term treatment of erosive oesophagitis. Aliment Pharmacol Ther 1993; 7: 67-73.
22. Orr WC, Mellow MH, Grossman MR. Patterns of 24-hour oesophageal acid exposure after acute withdrawal of acid suppression. Aliment Pharmacol Ther 1995; 9: 571-4.
23. Laursen LS, Havelund T, Bondesen S, et al. Omeprazole in the long-term treatment of gastro-oesophageal reflux disease: a double-blind randomized dose-finding study. Scand J Gastroenterol 1995; 30: 839-46.
24. Wilde MI, McTavish D. Omeprazole: an update of its pharmacology and therapeutic use in acid-related disorders. Drugs 1994; 48: 91-132.
25. Savarino V, Mela GS, Zentilin P, et al. Variability in individual response to various doses of omeprazole: implications for antiulcer therapy. Dig Dis Sci 1994; 39: 161-8.
26. Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121: 161-7.